ESR1 mutations are the most important alterations resulting in resistance to aromatase inhibitor treatment, and can be found in almost 40% of metastatic breast cancer patients [80] and in approximately 20% of patients with endocrine-resistant breast cancer [81]. Here, ESR1 is linked to breast carcinoma.